Charles River Laboratories International (CRL) Cash & Equivalents (2009 - 2026)

Charles River Laboratories International has reported Cash & Equivalents for 18 years, with the latest figure at $192.0 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 5.03% year-over-year to $192.0 million in Q2 2026; TTM through Jun 2026 was $192.0 million, a 5.03% increase from a year earlier, with the FY2025 full-year figure at $213.8 million, up 9.85% from the prior year.
• Cash & Equivalents was $192.0 million for Q2 2026 at Charles River Laboratories International, roughly flat from $191.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $327.0 million in Q1 2024, with the low at $157.2 million in Q3 2023.
• Average Cash & Equivalents over 5 years is $213.0 million, with a median of $201.0 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents slumped 48.03% in 2022, then surged 62.23% in 2024.
• Over 5 years, Cash & Equivalents stood at $233.9 million in 2022, then advanced by 18.32% to $276.8 million in 2023, then dropped by 29.69% to $194.6 million in 2024, then advanced by 9.85% to $213.8 million in 2025, then decreased by 10.17% to $192.0 million in 2026.
• The last three Cash & Equivalents figures came in at $192.0 million (Q2 2026), $191.8 million (Q1 2026), and $213.8 million (Q4 2025), per Business Quant data.